We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Taisho/Tanabe

This article was originally published in The Tan Sheet

10 Dec 2001

News

Executive Summary

Japanese pharmaceutical firms terminate plans to form joint holding company that would have created country's third largest drug maker, Tanabe Seiyaku announces Dec. 3. "Differences regarding the most appropriate direction to be pursued post-merger, in addition to the differences existing in the companies' fundamental infrastructure, makes it unlikely for the companies to be able to take full advantage of their respective strengths and specialties or bring increased value to stockholders," Tanabe states. Under the plan, Taisho - Japan's top OTC producer - would have absorbed Tanabe's OTC business, while Tanabe would have integrated Taisho's Rx operations (1"The Tan Sheet" Sept. 24, In Brief)...